AD109 Explored for Sleep Apnea in Patients Using GLP-1 Medications

Obstructive Sleep Apnea (OSA) is a common condition where breathing repeatedly stops and starts during sleep, leading to fragmented sleep and potential long-term health issues. Many individuals with OSA also manage other metabolic conditions, often with medications like GLP-1 receptor agonists (e.g., Tirzepatide, Semaglutide, Liraglutide). While AD109 (a combination of aroxybutynin/atomoxetine) is being developed for OSA, its safety and efficacy profile in patients concurrently taking GLP-1 drugs has been unknown. This Phase 2 study specifically addresses the potential interactions and comparative outcomes of AD109 in OSA patients who are also on GLP-1 therapies.

This Phase 2 study has completed, but specific efficacy and safety data for AD109 in patients with Obstructive Sleep Apnea (OSA), both with and without concurrent GLP-1 medication use, are not yet publicly available. The primary objective was to assess the safety and tolerability of AD109 in these two distinct patient groups, looking for any significant differences in adverse event rates or severity. Researchers also aimed to evaluate the impact of AD109 on OSA severity, likely measured by metrics such as the Apnea-Hypopnea Index (AHI), and to determine if the therapeutic benefits varied between the cohorts. Once released, the results are expected to detail any significant differences in adverse event rates and therapeutic benefits between the GLP-1-using cohort and the non-GLP-1 cohort, providing crucial insights into potential drug interactions or synergistic effects. > The most important finding, once published, will be the determination of whether AD109 maintains a comparable safety and efficacy profile in patients concurrently taking Tirzepatide, Semaglutide, or Liraglutide compared to those not on GLP-1 therapies.